Pimecrolimus
Back to searchMolecule Structure
Scientific Name
Pimecrolimus
Description of the Drug
Pimecrolimus is a topical calcineurin inhibitor used in the treatment of mild-moderate atopic dermatitis who are not candidates for other types of therapy due to previous lack of response or other reasons.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00337
http://www.drugbank.ca/drugs/DB00337
Brand Name(s)
Elidel
Company Owner(s)
Glenmark Pharmaceuticals Ltd, Actavis Laboratories Ut Inc Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc, Bausch Health Us Llc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
FK506-binding protein 1A | SINGLE PROTEIN | INHIBITOR | CHEMBL1902 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL438880 | |
DrugBank | DB00337 | |
PubChem: Thomson Pharma | 14791428 | 14767061 |
PubChem | 6509979 | |
LINCS | LSM-45937 | |
BindingDB | 50248356 | |
DrugCentral | 2168 | |
ChemicalBook | CB71086808 | |
Guide to Pharmacology | 6783 | |
rxnorm | PIMECROLIMUS | ELIDEL |
PubChem: Drugs of the Future | 12014634 | |
ChEBI | 135888 | |
ZINC | ZINC000085536990 |